Physician
NPI deactivated
Wilmington Health PLLC
Wilmington Health PLLC was paid $9.97M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 42% of everything it billed.
33Billing provider infoWILMINGTON HEALTH PLLC
WILMINGTON, NC 28401
WILMINGTON, NC 28401
33aNPI1639365562assigned 09/25/2007
33bProvider typePediatrics Physician
28Total paid$9.97M
24GClaims442,224
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in North Carolina
Rank by total paid#33 of 433
Median peer was paid$942K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,998 | $1.42M | |
| 2019 | 58,726 | $1.55M | |
| 2020 | 46,898 | $1.13M | |
| 2021 | 77,676 | $1.75M | |
| 2022 | 86,550 | $1.89M | |
| 2023 | 73,245 | $1.38M | |
| 2024incomplete | 54,131 | $847K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 42% | 50,198 | 41,611 | $4.15M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 19,261 | 14,968 | $1.08M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.5% | 8,467 | 7,299 | $752K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.9% | 7,888 | 6,673 | $689K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 4.6% | 26,729 | 21,683 | $458K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.5% | 5,353 | 4,486 | $445K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.1% | 4,270 | 3,560 | $405K |
| 99199 | Unlisted special service, procedure or report | 4.0% | 103,639 | 88,355 | $404K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 3.2% | 11,772 | 9,723 | $320K |
| 99051 | 1.4% | 6,496 | 5,121 | $142K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.3% | 15,711 | 13,019 | $134K |
| 87428 | 1.3% | 2,419 | 1,721 | $125K |
60 more codes
| D0145 | Oral evaluation for a patient under three years of age | 1.1% | 3,433 | $111K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.1% | 946 | $106K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 883 | $97K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,652 | $89K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,489 | $84K |
| 96127 | <1% | 19,373 | $73K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 981 | $66K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,606 | $61K |
| D1206 | Topical application of fluoride varnish | <1% | 3,391 | $48K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,092 | $28K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 515 | $16K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 296 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,003 | $7K |
| 90686 | <1% | 12,458 | $7K | |
| 90651 | <1% | 355 | $7K | |
| 90474 | <1% | 364 | $7K | |
| 80061 | Lipid panel | <1% | 407 | $6K |
| 92551 | <1% | 18,433 | $6K | |
| 94664 | <1% | 384 | $4K | |
| 90734 | <1% | 302 | $4K | |
| 88738 | <1% | 627 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 355 | $3K |
| 94060 | <1% | 106 | $3K | |
| 87807 | <1% | 266 | $3K | |
| 99173 | <1% | 19,715 | $3K | |
| 94010 | <1% | 108 | $2K | |
| 96160 | <1% | 670 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 93 | $2K |
| 87420 | <1% | 126 | $2K | |
| 84439 | <1% | 156 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 183 | $2K |
| 80053 | Comprehensive metabolic panel | <1% | 159 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 138 | $2K |
| 81003 | <1% | 833 | $1K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 313 | $824.36 |
| 99441 | <1% | 17 | $403.76 | |
| 83655 | <1% | 50 | $383.00 | |
| 90670 | <1% | 2,616 | $235.49 | |
| 85018 | <1% | 80 | $187.09 | |
| 3078F | <1% | 33,040 | $115.34 | |
| 85027 | <1% | 12 | $87.78 | |
| 3074F | <1% | 38,242 | $42.41 | |
| 90723 | 0% | 856 | $0.00 | |
| 90680 | 0% | 669 | $0.00 | |
| 3044F | 0% | 322 | $0.00 | |
| 90647 | 0% | 733 | $0.00 | |
| 90660 | 0% | 16 | $0.00 | |
| 3079F | 0% | 138 | $0.00 | |
| 90656 | 0% | 57 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 54 | $0.00 |
| 90677 | 0% | 38 | $0.00 | |
| 90620 | 0% | 14 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 19 | $0.00 |
| 36416 | 0% | 12 | $0.00 | |
| 90461 | 0% | 398 | $0.00 | |
| 90672 | 0% | 132 | $0.00 | |
| 90685 | 0% | 32 | $0.00 | |
| 90633 | 0% | 98 | $0.00 | |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 62 | $0.00 |
| 90710 | 0% | 103 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHACE, CHASITY (DIRECTOR BUSINESS SERVICES)